Medical Comorbidities in MECP2 Duplication Syndrome: Results from the International MECP2 Duplication Database.
Daniel TaJenny DownsGareth BaynamAndrew WilsonPeter RichmondHelen LeonardPublished in: Children (Basel, Switzerland) (2022)
Since the discovery of MECP2 duplication syndrome (MDS) in 1999, efforts to characterise this disorder have been limited by a lack of large datasets, with small case series often favouring the reporting of certain conditions over others. This study is the largest to date, featuring 134 males and 20 females, ascertained from the international MECP2 Duplication Database (MDBase). We report a higher frequency of pneumonia, bronchitis, bronchiolitis, gastroesophageal reflux and slow gut motility in males compared to females. We further examine the prevalence of other medical comorbidities such as epilepsy, gastrointestinal problems, feeding difficulties, scoliosis, bone fractures, sleep apnoea, autonomic disturbance and decreased pain sensitivity. A novel feature of urinary retention is reported and requires further investigation. Further research is required to understand the developmental trajectory of this disorder and to examine the context of these medical comorbidities in a quality of life framework.
Keyphrases
- healthcare
- adverse drug
- chronic pain
- case report
- mental health
- physical activity
- deep learning
- escherichia coli
- biofilm formation
- high throughput
- bone mineral density
- pain management
- intensive care unit
- quality improvement
- emergency department
- heart rate
- staphylococcus aureus
- depressive symptoms
- soft tissue
- electronic health record
- body composition
- bone regeneration
- candida albicans
- respiratory syncytial virus
- drug induced